Erratum To: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Abstract

This editorial expression of concern is to alert our readership that the data presented in Figures 4 and 5 require further analysis and verification. The scientific record will be updated once this process has been completed. J.T.R., P.L.v.L., R.F., D.I., E.N., G.W., P.S., C.K., D.T.S., and G.H. agree. The other authors could either not be reached or did not provide a response.